Wells Fargo Sticks to Their Buy Rating for Xenon (XENE)
In a report released today, Benjamin Burnett from Wells Fargo maintained a Buy rating on Xenon, with a price target of $68.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Burnett covers the Healthcare sector, focusing on stocks such as Xenon, Ultragenyx Pharmaceutical, and Axsome Therapeutics. According to TipRanks, Burnett has an average return of -2.5% and a 39.31% success rate on recommended stocks.
In addition to Wells Fargo, Xenon also received a Buy from Deutsche Bank ‘s David Hoang in a report issued today. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on Xenon (NASDAQ: XENE).
Based on Xenon’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $105.26 million. In comparison, last year the company had a GAAP net loss of $65.69 million
Read More on XENE:
Disclaimer & DisclosureReport an Issue
- Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
- Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo
- Biohaven price target raised to $27 from $24 at Goldman Sachs
- Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs
- Xenon Pharmaceuticals price target raised to $74 from $53 at H.C. Wainwright
